Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
NCT06926842 on ClinicalTrials.gov · last registry update 2026-08-21
Closed to new participants; the 221 already enrolled are still being followed. Its estimated completion date, 13 August 2026, has passed with no update to the record. Primary outcome, as filed: Percentage Change in Body Weight. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. petrelintide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P2
- Drug
- petrelintide
- Sponsor
- Zealand Pharma
- Sponsor type
- Industry
- Enrollment
- 221
- Started
- 2025-04-22
- Primary completion
- 2026-08-13 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percentage Change in Body Weight
Conditions studied
Overweight · Type 2 Diabetes · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the petrelintide page for this molecule’s full trial and approval history.